Pricing, UK Biotech

Biogen’s big breakthrough drug Spinraza runs into a barrier as NICE turns thumbs down on reimbursement

People

Pfizer Oncology loses its CMO to Allergan as cancer exec Charles Hugh-Jones makes a career leap

People, Politics

CEO interrupted: Novartis chief Narasimhan looks to new ethics czar to clean up after the lingering Cohen mess
More news caret

calendar Protocols

Quick hits from around the biopharma web

Aug 14

Acorda CTO Batycky is jumping ship to run a biotech; Motif gets a PDUFA date

Aug 13

After insider trading scandal, US congressman drops campaign — but stays on the ballot; Junshi Biosciences applies for Hong Kong IPO

Aug 10

After mixed pipeline updates, RegenXBio to raise $175M in offering; BioElectron closes $40M to prep late-stage mitochondrial drug

Aug 9

Ligand acquires Vernalis at bargain price of $43M; Pfizer, Novo back $60M round for dwarfism biotech

More Protocols caret

Dollar Premium

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

Top 10 pipeline blowups, setbacks and snafus in H1 2018

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?

12 top China VCs you need to know who are making a transpacific splash (Part 2)

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

twitter Marco

Hot BioTwitter bot - last updated ago

arrow-thick Most Viral

Biogen's pricey muscle drug Spinraza too costly for Britain

Reuters Reuters Editorial a day

Why Regenxbio's eye gene therapy would have to be the cheapest yet

Evaluate.com a day

Acorda CTO Batycky is jumping ship to run a biotech; Motif gets a PDUFA date

ENDPOINTS NEWS John Carroll a day

Cigna-Express Scripts deal gets backing from another proxy firm

Reuters Reuters Editorial a day

Gilead patent for its hepatitis C drug is invalidated by Chinese authorities - STAT

STAT a day

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

ENDPOINTS NEWS John Carroll a day

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Nature Biotechnology Sarwish Rafiq a day

Unum Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire News Room Unum Therapeutics Inc. a day

Biogen's big breakthrough drug Spinraza runs into a barrier as NICE turns thumbs down on reimbursement

ENDPOINTS NEWS John Carroll a day

Cory Wiegert Named New CEO of CancerLinQ LLC

ASCO a day

timer Latest

WSJ

Insurer Stops Reimbursing For Some MiMedx Products

ENDPOINTS NEWS

Acorda CTO Batycky is jumping ship to run a biotech; Motif gets a PDUFA date

WSJ

Ex-Playmate Alleging Trump Affair to Get Men's Journal Cover

ENDPOINTS NEWS

Biogen's big breakthrough drug Spinraza runs into a barrier as NICE turns thumbs down on reimbursement

FierceBiotech

Batycky exits Acorda to head up new biotech

FierceBiotech

Realm tanks, again, as second drug fails phase 2

FierceBiotech

Bioverativ executive Rogerio Vivaldi to helm cell therapy producer Sigilon

Chimeraresearchgroup

Bellus - David vs. Goliath Can BLU Deliver A Better Chronic Cough Drug Than Merck?

FDALawBlog

FDA's IVD TA: It's Not Just Technical Assistance

Novartis

Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer

fire Hot This Week

1

WSJ

New Marijuana-Based Epilepsy Treatment to Cost $32,500 a Year

2

FDA

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease

3

WSJ

CVS Gets a Boost From More Prescription Sales

4

BusinessWire

GRAIL Announces Appointment of Hal Barron and Hans Bishop to its Board of Directors

5

WSJ

FDA Approves First Drug Based on 'Gene-Silencing' Research

6

FDA

FDA approves new treatment for a rare genetic disorder, Fabry disease

7

Science | AAAS

The future of humans as model organisms

8

Nature

CRISPR 'barcodes' map a mammalian development in equisite details

9

MIT Technology Review

US scientist who edited human embryos with CRISPR responds to critics

10

Forbes

RegenX Bio Gene Therapy Shows Early Promise In Macular Degeneration

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back